Lista de obras - Richard M. Nixon - Dominio Público Uruguay

A Bayesian approach to probabilistic sensitivity analysis in structured benefit-risk assessment

artículo científico publicado en 2015

A case study using the PrOACT-URL and BRAT frameworks for structured benefit risk assessment.

artículo científico publicado en 2015

A comparison of clinical assessment with ultrasound in the management of secondary postpartum haemorrhage.

artículo científico publicado en 2002

Addressing the issues that arise in analysing multicentre cost data, with application to a multinational study

artículo científico publicado en 2006

Bayesian evaluation of breast cancer screening using data from two studies

artículo científico publicado en 2003

Bayesian hierarchical models for cost-effectiveness analyses that use data from cluster randomized trials

artículo científico publicado en 2009

Benefit-risk assessment in a post-market setting: a case study integrating real-life experience into benefit-risk methodology.

artículo científico publicado en 2014

Biologic drugs for rheumatoid arthritis in the medicare program: A cost-effectiveness analysis

article

Comment on: Modelling the cost effectiveness of TNF- antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry: reply

scholarly article by Nick Bansback et al published 25 April 2008 in Rheumatology

Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population

artículo científico publicado en 2009

Costs and quality of life of multiple sclerosis in the United Kingdom

artículo científico publicado en 2006

Developing appropriate methods for cost-effectiveness analysis of cluster randomized trials

scientific article published on 19 October 2011

Efficacy and safety of diclofenac in osteoarthritis: Results of a network meta-analysis of unpublished legacy studies

artículo científico

High correlation of VAS pain scores after 2 and 6 weeks of treatment with VAS pain scores at 12 weeks in randomised controlled trials in rheumatoid arthritis and osteoarthritis: meta-analysis and implications.

artículo científico publicado en 2015

How sensitive are cost-effectiveness analyses to choice of parametric distributions?

scientific article published on 01 July 2005

Implications for the human food chain of models of cadmium accumulation in sheep

artículo científico publicado en 2005

Imputation of a true endpoint from a surrogate: application to a cluster randomized controlled trial with partial information on the true endpoint

artículo científico publicado en 2003

Indirect comparisons of ranibizumab and dexamethasone in macular oedema secondary to retinal vein occlusion

artículo científico publicado en 2014

Meta-analysis of feeding trials investigating cadmium accumulation in the livers and kidneys of sheep

scientific article published on 01 February 2004

Methods for covariate adjustment in cost-effectiveness analysis that use cluster randomised trials

artículo científico publicado en 2012

Methods for incorporating covariate adjustment, subgroup analysis and between-centre differences into cost-effectiveness evaluations

artículo científico publicado en 2005

Modelling the cost effectiveness of TNF- antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry

article

Multilevel models for cost-effectiveness analyses that use cluster randomised trial data: An approach to model choice

artículo científico publicado en 2013

Multilevel models for estimating incremental net benefits in multinational studies.

artículo científico publicado en 2007

Network meta-analysis combining individual patient and aggregate data from a mixture of study designs with an application to pulmonary arterial hypertension

artículo científico publicado en 2015

No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis

artículo científico publicado en 2014

Non-parametric methods for cost-effectiveness analysis: the central limit theorem and the bootstrap compared

artículo científico publicado en 2010

Parametric modelling of cost data in medical studies.

artículo científico publicado en 2004

Parametric modelling of cost data: some simulation evidence

artículo científico publicado en 2005

Re: Hutchinson M, Fox RJ, Havrdova E, et al. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison. Curr

artículo científico publicado en 2014

Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis

artículo científico publicado en 2015

Review and comparison of methodologies for indirect comparison of clinical trial results: an illustration with ranibizumab and aflibercept

artículo científico publicado en 2016

Statistical methods for cost-effectiveness analyses that use data from cluster randomized trials: a systematic review and checklist for critical appraisal

artículo científico publicado en 2011

The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation

artículo científico publicado en 2009

The distribution of the cost of multiple sclerosis in the UK: how do costs vary by illness severity?

scientific article published on 01 September 2007

The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK.

artículo científico publicado en 2007

The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons

artículo científico publicado en 2007

Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis

article

Using multilevel models for assessing the variability of multinational resource use and cost data.

artículo científico publicado en 2005

Using short-term evidence to predict six-month outcomes in clinical trials of signs and symptoms in rheumatoid arthritis

artículo científico publicado en 2009

Lista de obras de Richard M. Nixon

A Bayesian approach to probabilistic sensitivity analysis in structured benefit-risk assessment

A case study using the PrOACT-URL and BRAT frameworks for structured benefit risk assessment.

A comparison of clinical assessment with ultrasound in the management of secondary postpartum haemorrhage.

Addressing the issues that arise in analysing multicentre cost data, with application to a multinational study

Bayesian evaluation of breast cancer screening using data from two studies

Bayesian hierarchical models for cost-effectiveness analyses that use data from cluster randomized trials

Benefit-risk assessment in a post-market setting: a case study integrating real-life experience into benefit-risk methodology.

Biologic drugs for rheumatoid arthritis in the medicare program: A cost-effectiveness analysis

Comment on: Modelling the cost effectiveness of TNF- antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry: reply

Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population

Costs and quality of life of multiple sclerosis in the United Kingdom

Developing appropriate methods for cost-effectiveness analysis of cluster randomized trials

Efficacy and safety of diclofenac in osteoarthritis: Results of a network meta-analysis of unpublished legacy studies

High correlation of VAS pain scores after 2 and 6 weeks of treatment with VAS pain scores at 12 weeks in randomised controlled trials in rheumatoid arthritis and osteoarthritis: meta-analysis and implications.

How sensitive are cost-effectiveness analyses to choice of parametric distributions?

Implications for the human food chain of models of cadmium accumulation in sheep

Imputation of a true endpoint from a surrogate: application to a cluster randomized controlled trial with partial information on the true endpoint

Indirect comparisons of ranibizumab and dexamethasone in macular oedema secondary to retinal vein occlusion

Meta-analysis of feeding trials investigating cadmium accumulation in the livers and kidneys of sheep

Methods for covariate adjustment in cost-effectiveness analysis that use cluster randomised trials

Methods for incorporating covariate adjustment, subgroup analysis and between-centre differences into cost-effectiveness evaluations

Modelling the cost effectiveness of TNF- antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry

Multilevel models for cost-effectiveness analyses that use cluster randomised trial data: An approach to model choice

Multilevel models for estimating incremental net benefits in multinational studies.

Network meta-analysis combining individual patient and aggregate data from a mixture of study designs with an application to pulmonary arterial hypertension

No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis

Non-parametric methods for cost-effectiveness analysis: the central limit theorem and the bootstrap compared

Parametric modelling of cost data in medical studies.

Parametric modelling of cost data: some simulation evidence

Re: Hutchinson M, Fox RJ, Havrdova E, et al. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison. Curr

Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis

Review and comparison of methodologies for indirect comparison of clinical trial results: an illustration with ranibizumab and aflibercept

Statistical methods for cost-effectiveness analyses that use data from cluster randomized trials: a systematic review and checklist for critical appraisal

The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation

The distribution of the cost of multiple sclerosis in the UK: how do costs vary by illness severity?

The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK.

The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons

Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis

Using multilevel models for assessing the variability of multinational resource use and cost data.

Using short-term evidence to predict six-month outcomes in clinical trials of signs and symptoms in rheumatoid arthritis